Literature DB >> 1516981

Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism--long-term follow-up.

E Vicari1, A Mongioì, A E Calogero, M L Moncada, G Sidoti, P Polosa, R D'Agata.   

Abstract

The effects of long-term (14-120 months) hCG-treatment of 17 male patients affected by isolated hypogonadotrophic hypogonadism (IHH) on testicular volume, plasma testosterone levels, and sperm concentration were assessed. Mean testicular volume increased from 3.8 +/- 0.2 (Mean +/- SEM) ml to a maximal of 14.9 +/- 1.1 ml after 22.2 +/- 2.3 months of hCG treatment. Maximal testicular volume correlated positively with the volume recorded before the patients had undergone any previous treatment. Testicular growth was also analysed by sorting the patients into two sub-groups according to whether their initial testicular volume was less than 4 ml (small testis subset, STS) or greater than or equal to 4 ml (large testis subset, LTS), supposedly indicating complete or partial gonadotrophin deficiency, respectively. Testicular volumes in the LTS group were always greater than those of the STS. Plasma testosterone levels reached adulthood values during hCG treatment and no statistically significant difference was detected between LTS and STS patients with IHH. Thirteen patients (70%) became sperm-positive during treatment with hCG alone; five out of eight (60%) were STS patients and eight out of nine (90%) were LTS. In addition, LTS patients always had a greater sperm output than did STS patients. Sperm concentration correlated positively with maximal testicular volume, but not with patient age, length of treatment, or initial testicular volume. The administration of hMG to eight of these patients caused an increase in testicular volume in two patients but the mean volume was not statistically different from that recorded at the end of treatment with hCG alone. Similarly, sperm concentration improved in three patients but again it did not differ significantly from that achieved in the course of hCG treatment. It is noteworthy that one patient became sperm-positive after the addition of hMG to his therapeutic regimen. Among sperm-positive patients attempting conception, seven out of 10 succeeded, two of whom were from the STS group. In summary, this study indicates that hCG alone is an effective treatment to induce complete spermiogenesis in IHH patients regardless of their initial testicular volume. However, a number of IHH patients may benefit from the addition of hMG in terms of testicular volume, sperm output, and pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516981     DOI: 10.1111/j.1365-2605.1992.tb01131.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  25 in total

Review 1.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  [Kallmann syndrome].

Authors:  A Mokosch; C Bernecker; H S Willenberg; N J Neumann
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

3.  Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spermatogenesis and fertility in hypogonadotropic hypogonadism.

Authors:  A A Sinisi; D Esposito; G Bellastella; L Maione; V Palumbo; L Gandini; F Lombardo; A De Bellis; A Lenzi; A Bellastella
Journal:  J Endocrinol Invest       Date:  2010-04-30       Impact factor: 4.256

4.  Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience.

Authors:  Luo Yang; Si Xiao Zhang; Qiang Dong; Zi Bing Xiong; Xiang Li
Journal:  Int Urol Nephrol       Date:  2011-10-12       Impact factor: 2.370

Review 5.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

6.  The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Barbonetti; A E Calogero; G Balercia; A Garolla; C Krausz; S La Vignera; F Lombardo; E A Jannini; M Maggi; A Lenzi; C Foresta; A Ferlin
Journal:  J Endocrinol Invest       Date:  2018-02-01       Impact factor: 4.256

7.  Gonadotropin therapy in males with hypogonadotropic hypogonadism: factors affecting induction of spermatogenesis after gonadotropin replacement.

Authors:  H Fuse; T Akashi; T Kazama; T Katayama
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 8.  Hypopituitarism.

Authors:  Paola Ascoli; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile.

Authors:  Andjela Drincic; Onur Karamanoglu Arseven; Ernesto Sosa; Moises Mercado; Peter Kopp; Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism.

Authors:  Kohei Koyama; Hiroshi Masuda; Teruo Inamoto; Naoki Segawa; Haruhito Azuma; Yoji Katsuoka
Journal:  Reprod Med Biol       Date:  2009-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.